

## Scientific program

### Thursday 31th of March

8:30 – 9:30 Registration + welcome coffee

9:30 – 9:45 Welcome and Opening Remarks

9:45 - 10:20 Introductory lecture

Janice Reichert (Reichert Biotechnology Consulting LLC, USA) – **Antibody therapeutics: Trends and challenges of development in indications that are not cancer or immune-mediated disorders.**

10:20 – 11:20 Session 1: Anti-infectious mAbs (*chairman: G. Desoubeaux, S. Ehrmann*)

10:20, Matthew Sleeman (Medimmune, UK) – **Targeting pathogens in respiratory disease**

10:55, Thomas Secher (INSERM U1220, France) - **Preclinical efficacy of Panobacumab (KBPA101) against acute Pseudomonas aeruginosa induced pneumonia**

11:15 – 11:40 Coffee break

11:40 – 12:35 Session 2: anti-cancer mAbs (*chairman: J. Reichert, H. Watier*)

11:40, Karen Reckamp (City of Hope, USA) - **Advances in antibody-based therapeutics for lung cancer**

12:15, Rita De Santis (Sigma Tau SpA, Italy) - **AvidinOX for lung cancer treatment with low dose biotinylated antibodies**

12:35 – 13:45 Lunch break

13:45 – 15:00 Session 3: mAbs in asthma (*chairman: E. Lemarié, C. Page*)

13:45, Roly Foulkes (Hammel Consulting, UK) – **The opportunities for antibody therapies in asthma**

14:20, Bernhard Ryffel (UMR 7355 CNRS-University of Orleans, France) - **Interleukin 17 receptor A (IL-17RA) dependent allergic lung inflammation to house dust mite in mice**

14:40, Harshad P. Patil (University of Louvain, Belgium) - **Impact of PEGylation on biodistribution and efficacy of antibody fragments after pulmonary delivery**



15:00 – 15:55      Session 4: antibody format (*chairman: A. Fontayne, R. Urbain*)

15:00, Jörg Adamczewski (Sanofi/Genzyme, France) - **The challenges & opportunities of multispecific antibodies at the example of the IL-4/IL-13 bispecific antibody SAR156597**

15:35, Jean-François Gestin (INSERM U892 – CNRS 6299 of Nantes, France) – **coming soon**

15:55 – 16:20      Coffee break and poster session

16:20 – 17:50      Session 5: inhaled antibodies (*chairman: N. Heuzé-Vourc'h, P. Cavaillon*)

16:20, Terry Sweeney (Nektar Therapeutics, US) – **Inhaled antibody and antibody-based therapeutics for respiratory diseases**

16:55, Rita Vanbever (University of Louvain, Belgium) - **Impact of the antibody format on their fate in the lungs**

17:30 Renaud Respaud (CEPR INSERM U1100- University of Tours, France) - **Pulmonary delivery of monoclonal antibodies: feasibility and challenges**

17:50 – 18:20      Conclusive clinical remarks

Patrice Diot (University of Tours, France)



## Friday 1<sup>st</sup> of April

8:30 – 9:00 Registration + welcome coffee

9:00 – 10:00 Session 6: animal models in respiratory diseases (*chairman: J. Guillemain, S. Lerondel*)

9:00, Caroline A. Owen (Brigham and Women's Hospital, Harvard Institutes, US) - **Novel animal models of COPD**

9:35, Frédéric Ducancel (CEA Saclay, France) - **Development, characteristics and potential of Non-Human Primates models of respiratory infections**

9:55 – 11:00 Session 7: relevance of animal models (*chairman: A. Le Pape, N. Winter*)

9:55, Clive Page (King's College of London, UK) - **relevance of animal models for development of drugs for treatment of respiratory diseases**

10:30, Antoine Guillon (CEPR INSERM U1100- University of Tours, France) – **a novel method to monitor inhaled antibodies after lung deposition: lung microdialysis**

10:50, Stéphanie Blanc (Cynbiose, France) – **Development of a cynomolgus macaque model of infection with hRSV to evaluate therapeutic approaches**

11:10-11:45 Alain Le Pape/Stéphanie Lerondel (CIPA, Phenomin-Taam CNRS, France) - **Overview of imaging technology to explore the lungs**

11:45 Final remarks and conclusion

12:00 Lunch

